Tarsus Pharmaceuticals price target raised to $62 from $60 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $62 from $60 and keeps an Overweight rating on the shares. The firm increased estimates for the company ahead of the Q4 report.